


# Affinity Capillary Electrophoresis in Pharmaceuticals and Biopharmaceutics



edited by

Reinhard H. H. Neubert  
Hans-Hermann Rüttinger

# Affinity Capillary Electrophoresis in Pharmaceutics and Biopharmaceutics

edited by

Reinhard H. H. Neubert  
Hans-Hermann Rüttinger

*Martin-Luther-University Halle-Wittenberg  
Halle, Germany*



MARCEL DEKKER, INC.

NEW YORK • BASEL

**Library of Congress Cataloging-in-Publication Data**

A catalog record for this book is available from the Library of Congress.

**ISBN: 0-8247-0951-9**

This book is printed on acid-free paper.

**Headquarters**

Marcel Dekker, Inc.

270 Madison Avenue, New York, NY 10016

tel: 212-696-9000; fax: 212-685-4540

**Eastern Hemisphere Distribution**

Marcel Dekker AG

Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland

tel: 41-61-260-6300; fax: 41-61-260-6333

**World Wide Web**

<http://www.dekker.com>

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above.

**Copyright © 2003 by Marcel Dekker, Inc. All Rights Reserved.**

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

**PRINTED IN THE UNITED STATES OF AMERICA**

# Affinity Capillary Electrophoresis in Pharmaceutics and Biopharmaceutics

# DRUGS AND THE PHARMACEUTICAL SCIENCES

## Executive Editor

**James Swarbrick**

*PharmaceuTech, Inc.  
Pinehurst, North Carolina*

## Advisory Board

Larry L. Augsburger	David E. Nichols
University of Maryland	Purdue University
Baltimore, Maryland	West Lafayette, Indiana

Douwe D. Breimer	Stephen G. Schulman
Gorlaeus Laboratories	University of Florida
Leiden, The Netherlands	Gainesville, Florida

Trevor M. Jones	Jerome P. Skelly
The Association of the	Alexandria, Virginia
British Pharmaceutical Industry	
London, United Kingdom	

Hans E. Junginger	Felix Theeuwes
Leiden/Amsterdam Center	Alza Corporation
for Drug Research	Palo Alto, California
Leiden, The Netherlands	

Vincent H. L. Lee	Geoffrey T. Tucker
University of Southern California	University of Sheffield
Los Angeles, California	Royal Hallamshire Hospital
	Sheffield, United Kingdom

Peter G. Welling  
Institut de Recherche Jouveinal  
Fresnes, France

## Preface

Since the pioneering accomplishments of Hjertén (1) and particularly of Jorgenson and Lukacs (2), capillary electrophoresis (CE) has undergone a dynamic development, producing a variety of applications. In chemical and pharmaceutical analysis, CE was employed mainly to separate and quantify drugs; this subject has recently been reviewed (3). The implementation of CE in quality control or drug profiling in biological systems has been illustrated in numerous studies. Capillary electrophoresis separations can be performed in different modes, using the same technical equipment. Capillary zone electrophoresis (CZE) and micellar electrokinetic chromatography (MEKC), introduced by Terabe et al. (4), are most frequently employed.

In recent years, much of the research work in the pharmaceutical sciences was focused on the development of effective vehicle systems, such as micelles, microemulsions, and liposomes, for drugs that are critical with respect to bioavailability. Knowledge of this subject is a prerequisite to developing vehicle systems for special administration routes, such as dermal, transdermal, intravenous, and nasal.

In pharmaceuticals, therefore, simple and effective methods and procedures are needed to characterize the interactions of drugs with pharmaceutical excipients (polysaccharides, cyclodextrins, etc.) and vehicle systems (micelles, microemulsions, and liposomes) in order to optimize the load of vehicle systems with the drugs.

On the other hand, more and more research interest has been focused on the interactions of drugs and vehicle systems with biological target structures such as receptors (cells, proteins, nucleic acids, etc.). In recent years, interactions between proteins and nucleic acids were studied to generate artificial viral systems for gene therapy. Another interesting focus is the study of immunoreactions.

In biopharmaceutics, effective methods are strongly needed, not only to characterize the interactions of drugs and vehicles with biological structures in order to optimize pharmaceutical vehicle systems, but also to study the interactions between biological molecules and to investigate immunoreactions.

All experimental techniques used for measuring the affinity of one molecule for another are based on the measurement of changes in physicochemical properties of the drug, depending on the properties and the concentration of the interacting partner. Changes in size, charge, and other properties of the complex may result in measurable differences in molecular weight (size exclusion methods), sedimentation (ultracentrifugation), diffusion rate (immunodiffusion, equilibrium dialysis), spectroscopic properties (fluorescence quenching, spectral shift), and electrophoretic migration.

In recent years, classic CE has been modified in several ways. This book, therefore, first gives a brief introduction to the principles and techniques of CE (Chapter 1).

Affinity capillary electrophoresis (ACE) relates changes in the electrophoretic mobility of a drug (analyte) after complexation with a substrate (pharmaceutical excipient, vehicle system, and biological structure) present in the background electrolyte to the association constant  $K_A$ . The electrophoretic mobility of a molecule (drug) in free solution is proportional to its electrical charge,  $q$ , and inversely related to the hydrodynamic radius,  $r$ , which depends on the molecular mass,  $M$ . If the drug (injected as the sample) shows interaction with a substrate, its mobility should be shifted compared to the one obtained in free solution. A quantification is possible and leads to association constants. The principle of ACE as well as the methods for explaining and quantifying the results are described in Chapter 2.

Interaction equilibria, e.g., between drugs, excipients, vehicle systems, and biological structures, reflect the sum of interactions, which are nonspecific (hydrophobic) and specific (electrostatic dipole-dipole and dipole-induced dipole and hydrogen bonding). The soft method of ACE does not disturb the sensitive equilibria via any chemical modification.

In the past few years, the use of ACE in pharmaceuticals and biopharmaceutics has expanded to the following areas:

- To measure physicochemical and thermodynamical parameters of drugs
- To characterize the affinity of drugs to pharmaceutical excipients (polysaccharides, other native and synthetic polymers, cyclodextrins, etc.) and vehicle systems (micelles, microemulsions, and liposomes)
- To determine binding constants between drugs and biological structures (e.g., receptors, cells, peptide fragments), proteins (e.g., enzymes), nucleic acids, and plasmids
- To characterize interactions between biologically relevant molecules, e.g., protein–protein and protein–nucleic acid interactions, as well as immunoreactions

The first part of this book presents theoretical basics necessary to understand the principles and techniques of CE as well as ACE. This knowledge opens access to potential applications in pharmaceutics, e.g., the investigation of interaction partners improving the solubility of lipophilic and barely water-soluble drugs and the determination of the effects of amphiphilic ion-pairing or complexation reagents (e.g., pharmaceutical excipients) on the permeation as well as absorption behavior of hydrophilic drugs. ACE enables the calculation of equilibrium constants, which are a measure of the strength of interaction. Although MEKC and ACE are based on the same principle, the recent literature (as well as this book) discusses these methods separately. However, MEKC can be considered a special case of ACE, differing only in the mode of mathematical description. In addition, the general calculation of association constants ( $K_A$ ) and partition coefficients ( $K_P$ ) is described.

Part II starts with the possibilities of ACE for characterizing the relevant physicochemical properties of drugs such as lipophilicity/hydrophilicity as well as thermodynamic parameters such as enthalpy of solubilization. This part also characterizes interactions between pharmaceutical excipients such as amphiphilic substances (below CMC) and cyclodextrins, which are of interest for influencing the bioavailability of drugs from pharmaceutical formulations. The same holds for interactions of drugs with pharmaceutical vehicle systems such as micelles, microemulsions, and liposomes.

Part III presents the methods based on ACE for studying interactions of drugs and pharmaceutical vehicle systems with biological structures such as receptors, proteins, polysaccharides, and nucleic acids. This part also describes and discusses methods for characterizing protein–protein interactions and immunoreactions.

Part IV covers the relevance of new combination (i.e., hyphenation) techniques such as CE-ESI- (electrospray ionization) MS (mass spectrometry) and CE-ESI-TOF- (time of flight) MS for ACE.



This book outlines the fascinating possibilities of the application of ACE and related technologies in the most interesting emerging fields of pharmaceuticals (controlled drug delivery) and biopharmaceutics (drug targeting).

*Reinhard H. H. Neubert*

## REFERENCES

1. S Hjertén. Free Zone Electrophoresis. Almquist and Wiksells, Uppsala, Sweden, 1967.
2. JW Jorgenson, KD Lukacs. Zone electrophoresis in open-tubular glass capillaries. *Anal Chem* 53:1298–1302, 1981.
3. LA Holland, NP Chetwyn, MD Perkins, SM Lunte. Capillary electrophoresis in pharmaceutical analysis. *Pharm Res* 14:372–387, 1997.
4. S Terabe, K Otsuka, K Ichikawa, A Tsuchiya, T Ando. Electrokinetic separations with micellar solutions and open-tubular capillaries. *Anal Chem* 56:111–113, 1984.

## Contributors

**Gottfried Blaschke, Ph.D.** Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany

**Bezhan Chankvetadze, Ph.D.\*** Department of Chemistry, Tbilisi State University, Tbilisi, Georgia

**Caroline Engvall, M.Sc.Pharm.** Department of Biochemistry, Biomedical Center, Uppsala University, Uppsala, Sweden

**Peter C. Hauser, Ph.D.** Department of Chemistry, University of Basel, Basel, Switzerland

**Yasushi Ishihama, Ph.D.†** Analytical Research Laboratories, Eisai Co., Ltd., Tsukuba, Ibaraki, Japan

**Steffen Kiessig, Ph.D.** Business Unit Separation and Quantification, Solvias AG, Basel, Switzerland

---

\**Current affiliation:* Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.

†*Current affiliation:* Protein Interaction Laboratory, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.

**Andrea Kühn** Department of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle, Germany

**Robert J. Linhardt, Ph.D.** Departments of Chemistry, Medicinal and Natural Products Chemistry, and Chemical and Biochemical Engineering, University of Iowa, Iowa City, Iowa, U.S.A.

**Michael W. Linscheid, Ph.D.** Department of Chemistry, Humboldt Universität zu Berlin, Berlin, Germany

**Per Lundahl, Ph.D.** Department of Biochemistry, Biomedical Center, Uppsala University, Uppsala, Sweden

**Wenjun Mao, Ph.D.** Departments of Chemistry, Medicinal and Natural Products Chemistry, and Chemical and Biochemical Engineering, University of Iowa, Iowa City, Iowa, U.S.A.

**Yahya Mrestani, Ph.D.** Department of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, Martin-Luther-University Halle-Wittenberg, Halle, Germany

**Reinhard H. H. Neubert, Ph.D.** Department of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, Martin-Luther-University Halle-Wittenberg, Halle, Germany

**Manuela Plätzer, Ph.D.** Department of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, Martin-Luther-University Halle-Wittenberg, Halle, Germany

**Klaus Raith, Ph.D.** Department of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, Martin-Luther-University Halle-Wittenberg, Halle, Germany

**Hans-Hermann Rüttinger, Ph.D.** Department of Pharmacy, Institute of Pharmaceutical Chemistry, Martin-Luther-University Halle-Wittenberg, Halle, Germany

**Jörg Schiewe, Ph.D.** Boehringer Ingelheim Pharma KG, Ingelheim, Germany

**Maria A. Schwarz, Ph.D.** Department of Chemistry, University of Basel, Basel, Switzerland

**Charuwan Thanawiroon, M.S.** Departments of Chemistry, Medicinal and Natural Products Chemistry, and Chemical and Biochemical Engineering, University of Iowa, Iowa City, Iowa, U.S.A.

**Frank Thunecke, Ph.D.** Environmental Biotechnology Centre, UFZ Centre for Environmental Research, Leipzig, Germany

# Contents

<i>Preface</i>	iii
<i>Contributors</i>	ix
<b>Part I: Principles and Theory</b>	
1. Principles of Capillary Electrophoresis <i>Jörg Schiewe</i>	1
2. Theory of Affinity Electrophoresis <i>Hans-Hermann Rüttinger</i>	23
<b>Part II: Application of Affinity Capillary Electrophoresis in Pharmaceutics</b>	
3. Determination of Physicochemical Parameters <i>Yasushi Ishihama</i>	45
4. Affinity of Drugs to Excipients <i>Manuela Plätzer and Reinhard H. H. Neubert</i>	71

5. Affinity of Drugs to Pharmaceutical Vehicle Systems: Micelles <i>Maria A. Schwarz and Peter C. Hauser</i>	103
6. Affinity of Drugs to Pharmaceutical Vehicle Systems: Microemulsions <i>Yahya Mrestani</i>	125
7. Interaction of Drugs with Liposomes and Proteoliposomes <i>Caroline Engvall and Per Lundahl</i>	151
8. Interactions Between Chiral Drugs and Cyclodextrins <i>Gottfried Blaschke and Bezhan Chankvetadze</i>	175
Part III: Application of Affinity Capillary Electrophoresis in Biopharmaceutics	
9. Affinity of Drugs to Proteins and Protein-Protein Interactions <i>Steffen Kiessig and Frank Thunecke</i>	211
10. Affinity Capillary Electrophoresis: DNA Interactions with Peptides, Proteins, and Modified DNA <i>Michael W. Linscheid</i>	243
11. Characterization of Polysaccharide Interactions <i>Charuwan Thanawiroon, Wenjun Mao, and Robert J. Linhardt</i>	265
12. Characterization of Immunoreactions <i>Andrea Kühn, Steffen Kiessig, and Frank Thunecke</i>	303
Part IV: New Combination Techniques and Conclusions	
13. Hyphenation of Affinity Capillary Electrophoresis with Mass Spectrometry <i>Klaus Raith</i>	329
14. Conclusions <i>Reinhard H. H. Neubert and Hans-Hermann Rüttinger</i>	351
Index	355

## DRUGS AND THE PHARMACEUTICAL SCIENCES

A Series of Textbooks and Monographs

1. Pharmacokinetics, *Milo Gibaldi and Donald Perrier*
2. Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control, *Sidney H. Willig, Murray M. Tuckerman, and William S. Hitchings IV*
3. Microencapsulation, *edited by J. R. Nixon*
4. Drug Metabolism: Chemical and Biochemical Aspects, *Bernard Testa and Peter Jenner*
5. New Drugs: Discovery and Development, *edited by Alan A. Rubin*
6. Sustained and Controlled Release Drug Delivery Systems, *edited by Joseph R. Robinson*
7. Modern Pharmaceutics, *edited by Gilbert S. Banker and Christopher T. Rhodes*
8. Prescription Drugs in Short Supply: Case Histories, *Michael A. Schwartz*
9. Activated Charcoal: Antidotal and Other Medical Uses, *David O. Cooney*
10. Concepts in Drug Metabolism (in two parts), *edited by Peter Jenner and Bernard Testa*
11. Pharmaceutical Analysis: Modern Methods (in two parts), *edited by James W. Munson*
12. Techniques of Solubilization of Drugs, *edited by Samuel H. Yalkowsky*
13. Orphan Drugs, *edited by Fred E. Karch*
14. Novel Drug Delivery Systems: Fundamentals, Developmental Concepts, Biomedical Assessments, *Yie W. Chien*
15. Pharmacokinetics: Second Edition, Revised and Expanded, *Milo Gibaldi and Donald Perrier*
16. Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control, Second Edition, Revised and Expanded, *Sidney H. Willig, Murray M. Tuckerman, and William S. Hitchings IV*
17. Formulation of Veterinary Dosage Forms, *edited by Jack Blodinger*
18. Dermatological Formulations: Percutaneous Absorption, *Brian W. Barry*
19. The Clinical Research Process in the Pharmaceutical Industry, *edited by Gary M. Matoren*
20. Microencapsulation and Related Drug Processes, *Patrick B. Deasy*
21. Drugs and Nutrients: The Interactive Effects, *edited by Daphne A. Roe and T. Colin Campbell*
22. Biotechnology of Industrial Antibiotics, *Erick J. Vandamme*

23. *Pharmaceutical Process Validation*, edited by Bernard T. Loftus and Robert A. Nash
24. *Anticancer and Interferon Agents: Synthesis and Properties*, edited by Raphael M. Ottenbrite and George B. Butler
25. *Pharmaceutical Statistics: Practical and Clinical Applications*, Sanford Bolton
26. *Drug Dynamics for Analytical, Clinical, and Biological Chemists*, Benjamin J. Gudzinowicz, Burrows T. Younkin, Jr., and Michael J. Gudzinowicz
27. *Modern Analysis of Antibiotics*, edited by Adjoran Aszalos
28. *Solubility and Related Properties*, Kenneth C. James
29. *Controlled Drug Delivery: Fundamentals and Applications*, Second Edition, Revised and Expanded, edited by Joseph R. Robinson and Vincent H. Lee
30. *New Drug Approval Process: Clinical and Regulatory Management*, edited by Richard A. Guarino
31. *Transdermal Controlled Systemic Medications*, edited by Yie W. Chien
32. *Drug Delivery Devices: Fundamentals and Applications*, edited by Praveen Tyle
33. *Pharmacokinetics: Regulatory • Industrial • Academic Perspectives*, edited by Peter G. Welling and Francis L. S. Tse
34. *Clinical Drug Trials and Tribulations*, edited by Allen E. Cato
35. *Transdermal Drug Delivery: Developmental Issues and Research Initiatives*, edited by Jonathan Hadgraft and Richard H. Guy
36. *Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms*, edited by James W. McGinity
37. *Pharmaceutical Pelletization Technology*, edited by Isaac Ghebre-Sellassie
38. *Good Laboratory Practice Regulations*, edited by Allen F. Hirsch
39. *Nasal Systemic Drug Delivery*, Yie W. Chien, Kenneth S. E. Su, and Shyi-Feu Chang
40. *Modern Pharmaceutics: Second Edition, Revised and Expanded*, edited by Gilbert S. Banker and Christopher T. Rhodes
41. *Specialized Drug Delivery Systems: Manufacturing and Production Technology*, edited by Praveen Tyle
42. *Topical Drug Delivery Formulations*, edited by David W. Osborne and Anton H. Amann
43. *Drug Stability: Principles and Practices*, Jens T. Carstensen
44. *Pharmaceutical Statistics: Practical and Clinical Applications*, Second Edition, Revised and Expanded, Sanford Bolton
45. *Biodegradable Polymers as Drug Delivery Systems*, edited by Mark Chasin and Robert Langer
46. *Preclinical Drug Disposition: A Laboratory Handbook*, Francis L. S. Tse and James J. Jaffe
47. *HPLC in the Pharmaceutical Industry*, edited by Godwin W. Fong and Stanley K. Lam
48. *Pharmaceutical Bioequivalence*, edited by Peter G. Welling, Francis L. S. Tse, and Shrikant V. Dinghe



49. Pharmaceutical Dissolution Testing, *Umesh V. Banakar*
50. Novel Drug Delivery Systems: Second Edition, Revised and Expanded, *Yie W. Chien*
51. Managing the Clinical Drug Development Process, *David M. Cocchetto and Ronald V. Nardi*
52. Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control, Third Edition, *edited by Sidney H. Willig and James R. Stoker*
53. Prodrugs: Topical and Ocular Drug Delivery, *edited by Kenneth B. Sloan*
54. Pharmaceutical Inhalation Aerosol Technology, *edited by Anthony J. Hickey*
55. Radiopharmaceuticals: Chemistry and Pharmacology, *edited by Adrian D. Nunn*
56. New Drug Approval Process: Second Edition, Revised and Expanded, *edited by Richard A. Guarino*
57. Pharmaceutical Process Validation: Second Edition, Revised and Expanded, *edited by Ira R. Berry and Robert A. Nash*
58. Ophthalmic Drug Delivery Systems, *edited by Ashim K. Mitra*
59. Pharmaceutical Skin Penetration Enhancement, *edited by Kenneth A. Walters and Jonathan Hadgraft*
60. Colonic Drug Absorption and Metabolism, *edited by Peter R. Bieck*
61. Pharmaceutical Particulate Carriers: Therapeutic Applications, *edited by Alain Rolland*
62. Drug Permeation Enhancement: Theory and Applications, *edited by Dean S. Hsieh*
63. Glycopeptide Antibiotics, *edited by Ramakrishnan Nagarajan*
64. Achieving Sterility in Medical and Pharmaceutical Products, *Nigel A. Halls*
65. Multiparticulate Oral Drug Delivery, *edited by Isaac Ghebre-Sellassie*
66. Colloidal Drug Delivery Systems, *edited by Jörg Kreuter*
67. Pharmacokinetics: Regulatory • Industrial • Academic Perspectives, Second Edition, *edited by Peter G. Welling and Francis L. S. Tse*
68. Drug Stability: Principles and Practices, Second Edition, Revised and Expanded, *Jens T. Carstensen*
69. Good Laboratory Practice Regulations: Second Edition, Revised and Expanded, *edited by Sandy Weinberg*
70. Physical Characterization of Pharmaceutical Solids, *edited by Harry G. Brittain*
71. Pharmaceutical Powder Compaction Technology, *edited by Göran Alderborn and Christer Nyström*
72. Modern Pharmaceutics: Third Edition, Revised and Expanded, *edited by Gilbert S. Banker and Christopher T. Rhodes*
73. Microencapsulation: Methods and Industrial Applications, *edited by Simon Benita*
74. Oral Mucosal Drug Delivery, *edited by Michael J. Rathbone*
75. Clinical Research in Pharmaceutical Development, *edited by Barry Bleidt and Michael Montagne*